Clinical Trials

Open Search
Diseasesort descending Investigator Location Phase Trial Status Detail
Amyotrophic Lateral Sclerosis (ALS)
Namita Goyal, M.D.
UCI
  • Phase 3
Recruiting UCI's Trial in Neurological Diseases ( A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS )
Beta-Thalassemia
Gary Schiller, M.D.
UCLA
  • Phase 1/2
Recruiting UCLA's Trial in Blood Diseases ( A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) )
Critical Limb Ischemia
Isabella Jade Kuo, M.D.
UCI
  • Phase 3
Recruiting UCI's Trial in Blood Diseases ( Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization )
End-Stage Renal Disease
Roy Fujitani, M.D.
UCI
  • Phase 3
Recruiting UCI's Trial in Kidney Diseases ( A Phase 3 Study to Compare the Efficacy and Safety of Humacytes Human Acellular Vessel with that of an Autologous Arteriovenous Fistula in Subjects with End-Stage Renal Disease )
Glioblastoma
Daniela Bota, M.D., Ph.D.
UCI
  • Phase 2
Recruiting UCI's Trial in Cancer Diseases ( Phase II Trial of Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens (AV-GBM-1) as an Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma )
HIV
Ronald Mitsuyasu, M.D.
UCLA
  • Phase 1/2
Closed UCLA's Trial in HIV/AIDS Diseases ( Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection )
HIV
Ronald Mitsuyasu, M.D.
UCLA
  • Phase 1
Recruiting UCLA's Trial in HIV/AIDS Diseases ( A Pilot Study to Evaluate the Feasibility, Safety and Engraftment of Zinc Finger Nuclease (ZFN) CCR5 Modified CD34+ Hematopoietic Stem/Progenitor Cells (SB-728mR-HSPC) in HIV-1 (R5) Infected Patients )
Ischemic Stroke
Leonid Groysman, M.D.
UCI
  • Phase 2
Recruiting UCI's Trial in Neurological Diseases ( A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects With Disability Following an Ischemic Stroke )
Lung Cancer
Steven M. Dubinett, M.D.
UCLA
  • Phase 1
Recruiting UCLA's Trial in Cancer Diseases ( A Phase I Trial of Intratumoral Administration of CCL21-gene Modified Dendritic Cell (DC) Combined With Intravenous Pembrolizumab for Advanced NSCLC )
Multiple Myeloma
Sarah Larson, M.D.
UCLA
  • Phase 1
Closed UCLA's Trial in Cancer Diseases ( Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a High Dose Melphalan Conditioning Regimen, With Administration of Interleukin-2, in Patients With Multiple Myeloma )
Sarcoma/Solid Tumors
Theodore Scott Nowicki, M.D., Ph.D.;
UCLA
  • Phase 1
Recruiting UCLA's Trial in Cancer Diseases ( Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies )
Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency UCLA
  • Phase 1/2
Closed UCLA's Trial in Blood Diseases ( Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector for Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID) )
Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (Cryopreserved) UCLA
  • Phase 1/2
Active, Not Recruiting UCLA's Trial in Blood Diseases ( Efficacy and Safety of Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With Severe Combined Immunodeficiency Due to ADA Deficiency )
Sickle Cell Disease
Gary Schiller, M.D.;
UCLA
  • Phase 1
Recruiting UCLA's Trial in Diseases ( Clinical Research Study of Autologous Stem Cell Transplantation for Sickle Cell Disease (SCD) Using Peripheral Blood CD34+ Cells Modified With the Lenti/G-╬▓AS3-FB Lentiviral Vector )
Traumatic Brain Injury
Daniel C. Lu, M.D., Ph.D.
UCLA
  • Phase 2
Active, Not Recruiting UCLA's Trial in Neurological Diseases ( A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI) )
X-linked Chronic Granulomatous Disease (X-CGD) UCLA
  • Phase 1/2
Recruiting UCLA's Trial in Blood Diseases ( A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease )